Women with BRCA1 and BRCA2 gene mutations are at increased risk of breast cancer, compared with women who don't carry the mutation in familial and somatic condition is remains challenge. The aim of this work is to identify differentially expressed gene patterns related with BRCA1 and BRCA2 gene mutations that significantly expressed in breast cancer drug targets. We have developed microarray meta-analysis to predict differential gene expression levels between hereditary BRCA1 mutations linked with sporadic breast cancer, using statistical methods to identify upregulated and downregulated genes to perform meta-analysis; further SVM classifier to identify gene ranks and their associated gene networks helps to classify gene profiles used for drug targets. We have predicted 2381 upregulated and 2057 down regulated genes that significantly (p-value < 0.01) associated with BRCA1 and BRCA2 related gene mutations. We also predicted that SVM classifiers showing 810 genes significantly associated with 4 different types of which 592 genes is helpful for protein expression that shows metastatic condition. Based on gene-gene interaction network prediction showing 30 genes is significantly associated with GO terms and many signaling pathways; we mainly use these genes for potential drug targets. Furthermore this result helps predict anticancer drug targets.
Introduction
Cancer is a genetic disease that leads to uncontrolled cell proliferation. It is a multistep process arising from gene mutations involved in signaling, cell-cycle and/or cell-death pathways resulting in a mis-regulation of the pathways [1] .
These mutations produce an oncogene with a dominant function, and/or tumor suppressor genes causing a loss of function. Either ways, the cell cycle is disrupted leading to uncontrolled cell division and growth-a common feature of every cancer type [2] .
Breast cancer is a complex collection of diseases with characteristic clinical, histopathological, and molecular features [3] . Breast carcinogenesis involves genetic and epigenetic alterations that cause aberrant gene function [4] . The commencement and development of breast cancer is caused due to the gathering of genetic mutations which lead to abnormal cell functions [5] . These genetic mutations can be inherited or irregular and may lead to the activation of oncogenes and block tumor suppressor genes [5] . It is also shown that breast cancer can be caused by epigenetic alterations, which do not affect the primary DNA sequence but cause abnormal transcriptional regulation that causes a change in gene expression patterns involved in cellular proliferation, survival and differentiation [4] . Breast cancer is the most commonly occurring disease with around 1.38 million new breast cancer cases being diagnosed every year, globally [6] . It is also the most common cancer affecting women and stands second in causing cancer deaths among women [4] and fifth in cancer overall [6] . The survival of breast cancer patients is mainly associated with two factors-early detection of disease and adjuvant systemic treatment which includes chemotherapy and hormone therapy [3] . Treatments are largely dependent on clinic pathological conditions that include age, tumor size, histological grade, estrogen receptor (ER), progesterone receptor (PR), and HER2 status [3] . Although all patients with breast cancer are treated with chemotherapy, only a few patients will benefit from it [3] . Selecting an appropriate adjuvant therapy for breast cancer patients depends on reliable predictive markers [3] .
The microarray-based gene expression profiling has had a tremendous development in the past decade [3] . The discovery of this technology has been considered as a new dawn in cancer biology and oncology practice [3] . It has aided in the analysis of the multiple gene expression levels in a tumor sample [3] . With many gene expression profiling studies performed in the last decade, the datasets are available for analysis and meta-analysis [3] . Microarray-based gene expression profiling studies have helped in understanding the complexity of breast cancer which is not a simple disease but a collection of many genetic mutations [5] .
In this study, we used microarray-based gene expression profiling datasets of breast cancer from Gene Expression Omnibus (GEO) database to come up with significant gene set that can be used as initial set in developing predictive and prognostic markers specifically meant for breast cancer. This study also focuses on highlighting genes that are highly or lowly expressed in breast cancer which 
Material and Methods
In order to identify meta analysis of BRCA1, BRCA2, BRCA1/2 and normal genes involved in breast cancer of both familial, sporadic, familial cancer aggregation and normal cells that helps the role of gene expression in disease progression can be analyzed using raw microarray data. We need to determine the disease mechanism and the role of signaling pathways, 1) gene expression measurements 2) definitions of signaling pathways and 3) drug target identification.
Raw Data Selection
We searched public gene expression datasets from GEO microarray database to identify expression patterns neoadjusted chemotherapy patients were seriously affect gene expression patterns and profiles will identify used 3 different condi- 
Preprocessing of Raw Data
To make quality of data to identify differential expressed genes in breast cancer using different pre-processing techniques such as 1) filtering data of image intensity values 2) remove bias using null values filtering and normalization, 
Differential Expression Analysis
The limma package of affymetrix data is used to identify differential expressed genes in breast cancer. The simplest dataset features replicated designs and progress through experiments with two or more groups, direct designs and factorial designs of different time course experiments. To assign column names of a set creates contrast matrix to perform all pairwise comparisons to compute estimated coefficients and standard errors of a given datasets. The differential expression of the genes was analyzed by experimental shrinkage of the errors that leads arrive at a common value. This was attained by computing the t-statistics and log-odds of differential expression. It generates list of top 10 ("number = 10") differentially expressed genes sorted by B-values ("sort.by = B") for each of the three comparison groups ("coef = 1") in this sample set. The summary table has logFC is the log2-fold change, the AveExpr is the average of expression value across all arrays and channels, the moderated t-statistic (t) is the logFC to its standard error, the p value is the associated p-value, the adj. p value is the p-value adjusted for multiple testing and the B-value (B) is the log-odds that a gene is differentially expressed (the-higher-the-better). Usually one wants to base gene selection on the adjusted p-value rather than the t-or B-values. Filters out candidates that have p-values < 0.05 in each group ("coef = 1") and provides the number of candidates for each list. These numbers should be identical with the sum of the values in each circle of the above Venn diagram. Same as above, but with complex filter: p-value < 0.01 AND at least 2-fold change AND expression value A > 10. This function plots, heat diagram gene expression profiles of genes which are significantly differentially expressed in the primary condition (this is not a cluster analysis heat map). Genes are sorted by differential expression under the primary condition. The argument "primary = 1" selects the first contrast column in the "results" matrix as a primary condition.
Meta Analysis and Classification
Using geNETClassifier algorithm to classify the genes was differentially expressed in different disease datasets along with gene networks. The genome-wide association studies of expression sets or expression matrix files of ranked genes, probe sets of different variables is optimized with training sets.
Using multi-class SVM based classifier to quires genes chosen for classification; the mutual-information (interactions) and the co-expression (correlations) between the genes are also calculated and analyzed by the algorithm. These allow estimating the degree of association between the variables and they are used to generate a gene network for each class. These networks can be plotted, providing an integrated overview of the genes that characterized each disease (i.e. each class).
Functional Annotation and Enrichment Analysis
The functional enrichment of the differentially expressed was done using the Gene Ontology (GO) database. The classification of the gene function and loci 
Results and Discussion
In the current study, we have predicted the analysis of breast cancer genes that is 
Differential Gene Expression Analysis
After normalization of raw data by calculating foreground and background intensities of color of all probe sets is used to predict differential gene expression. (Figure 1 and Table 1 ).
Molecular Subtypes of BRCA1 Mutation Related Genes in Breast Cancer
The 
Differential Classification of BRCA2 Mutation Related Genes in Breast Cancer
The differential classification of BRCA2 mutation in breast cancer showed 22 upregulated and 40 downregulated genes. This gene mutation was found in ER cells of breast cancer. These genes have the post-transcriptional regulation (Mir9-2) in multicellular organisms that affect the stability and translation of mRNAs. The calcium dependent was governed by the CDH2 receptor genes.
The cell-cell adhesion of glycoprotein has the cadherin repeats of transmembrane regions, which are highly conserved. All these genes are present in at the top of the data (Table 3) .
Differential Expression of BRCAx Samples in Breast Cancer
The BRCAx is compared with sporadic samples of breast cancer shows 27 upregulated and 48 down regulated genes. The 10 top regulated genes such as CDH2
is common regulator of cell-cell adhesion in transmembrane protein, LOC645323
gene has transcriptional regulation in putative alternative promoters of breast cancer genes, RCBTB1 is interacts with the ACE2A receptor that regulate B-cell (Table 4) .
Differential Expression of Sporadic Gene Mutation Samples in Breast Cancer
In Sporadic gene mutation shows 18 upregulated genes and 98 down regulated genes that differentially expressed in sporadic genes. To evaluate the reproducibility of the expression patterns of the signatures shows LOC645323, CDH2, CYP27C1 RCBTB1 genes is significantly associated with transcriptional regulation within mutastatis. This revealed 18 Sporadic -98 Sporadic basal-like tumors in the RCBTB1 data set. The performance of the signature was estimated by LOC645323, using the SVM algorithm (Table 5 ).
Differential Expression of FCA Normal Tissues
The FCA with normal dataset has 42 upregulated and 46 down regulated genes that significantly associated with Breast cancer (Table 6 ).
Functional Enrichment
Based on functional annotation and enrichment analysis of familial, sporadic, BRCA1, BRCA2, BRCAx, FCA of both gene sets and functional categories can influence the results of functional enrichment analysis. In order to mitigate these effects, we suggest that instead of evaluating the overlap between 50 genes such as KCNJ3, MYST4, DSP, SLC6A4, EDDM3B, Six4, aqp11, Mir9-2, CDH2, GLC,
DOI: 10.4236/oalib.1105000 9 Open Access Library Journal Bnc1, RCBTB1, NPL and SHROOM2 gens traditionally done in functional enrichment analysis, one instead considers the overlap between the annotations made to a gene set and a branch of terms in the Gene Ontology. To accurately capture the significance of annotation overlap we develop a randomization scheme that preserves the transitive annotation features of the GO DAG while calculating the probability of obtaining a certain number of annotations between a gene set and a GO branch. (Figure 2 and Table 7 ). 
Significant Analysis of Breast Cancer Genes in Biomarkers

Gene Network Prediction
We used SVM method to construct network using geNETClassifier algorithm to isolation. The overall gene network is predicted in Figure 3 and top 30 gene signatures that predicted based on SVM Classifiers were represented in Figure 4 ( Table 8 ).
Conclusion
In the current study of developing Meta analysis of identification of BRCA1 mutated gene signatures present in breast cancer. There are 6 types of datasets such as familial of BRCA1, BRCA2, BRCAx, Sporadic, FCA and normal sets of specific gene signatures. We have identified 810 genes that significantly associated with all the types of datasets, based on protein expression only 592 genes that help to metastatic condition to compare primary tumors with a FDA < 0.1.
There are 52 genes involved in different pathways associated with metastasis. We have compared the list of genes in 6 independent groups which demonstrated that 30 genes is enriched for GO annotation significantly associated with different Open Access Library Journal pathways of all 6 types of datasets and these genes are mainly used for potential drug targets. Furthermore this result helps to identify metastatic signature which could facilitate further research in metastasis, such as outcome prediction, drug discovery, and other functional studies.
